Page 20 - Robert Kramer News Today

POLITICO Get the POLITICO Pulse newsletter Email Sign Up By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Presented by Editor’s Note: POLITICO Pulse is a free version of POLITICO Pro Health Cares morning newsletter, which is delivered to our subsc...

Johnson & Johnson documented contamination risks at Baltimore plant months before vaccine doses were ruined By Christopher Rowland The Washington Post,Updated May 19, 2021, 11:46 a.m. Email to a Friend Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill in Washington.Stefani Reynolds/Associated Press WASHINGTON - Johnson & Johnson documented contamination risks at a Baltimore biodefense plant in June 2020, se...

The U.S. government awarded the company a $628 million contract last year to help make coronavirus vaccines. Emergent did not immediately respond to CNBCs request for comment. The hearing Wednesday comes more than a month after the Biden administration put J&J in charge of the Baltimore plant after U.S. officials learned that Emergent, a federal contractor that had been making key ingredients for J&J and AstraZeneca, cross-contaminated ingredients for the two shots. "There are a significant ...

The FDA is holding over 100 million Johnson & Johnson Covid-19 vaccine doses for further testing, Emergent CEO Robert Kramer told lawmakers Wednesday.

Emergent CEO: J&J vaccine production could resume in days Nathaniel Weixel © Getty Emergent CEO: J&J vaccine production could resume in days Emergent BioSolutions could resume manufacturing doses of Johnson & Johnsons coronavirus vaccine "within a matter of days," the companys CEO Robert Kramer told a House panel Wednesday. Democratic lawmakers on the House Coronavirus Crisis Subcommittee pressed Kramer on Emergents ability to fix a host of manufacturing issues identified by ...

Executives defend quality control at troubled COVID-19 vaccine plant Emily Kopp © Provided by Roll Call Rep. Mariannette Miller-Meeks (R-IA) listens as Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during the hearing on the companys handling of COVID-19 vaccines. Executives at a vaccine contractor responsible for contaminating millions of vaccine doses defended its manufacturing quality Wednesday, even as new revelat...

They are potentially contaminated and may need to be discarded. The New York Times reported last month that the facility may have jeopardized 62 million of J&Js COVID-19 vaccine doses. Emergent BioSolutions CEO Robert G. Kramer admitted to the House of Representatives on Wednesday that more than 100 million doses of the Johnson & Johnson vaccine are on hold and possibly contaminated. It was the first time that Kramer admitted the high figure of potentially spoiled vaccines after The New York T...

Pool / Getty Images As Emergent BioSolutions Baltimore factory was throwing away unfinished COVID-19 vaccine doses and struggling to pass muster with the Food and Drug Administration, the company awarded at least $3 million in bonuses to a handful of executives, according to documents released by a congressional subcommittee Wednesday. The House Select Subcommittee on the Coronavirus Crisis grilled executives from Emergent, which was awarded a $628 million contract with the federal governm...

Emergent BioSolutions Inc told U.S. regulators it aims as soon as July to correct the problems at its manufacturing facility that ruined millions of COVID-19…

J&J vaccine production could restart in U.S. within days, Emergent executive testifies POLITICO 5 hrs ago By Sarah Owermohle © Stefani Reynolds/The New York Times via AP, Pool Robert Kramer, president and CEO of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill. Emergent BioSolutions could resume manufacturing Johnson & Johnsons Covid-19 vaccine within days, CEO Robert Kramer told a House panel Wednesday. The Food and Drug Administration ord...